X

Trial Profile

Phase I/Comparative Randomized Phase II Trial of TRC105 Plus Bevacizumab Versus Bevacizumab in Bevacizumab-Naïve Patients With Recurrent Glioblastoma Multiforme

Status: Completed

Phase of Trial: Phase I/II

Latest Information Update: 07 Nov 2021

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Bevacizumab (Primary) ; Carotuximab (Primary)
Indications Astrocytoma; Glioblastoma; Glioma; Gliosarcoma; Oligodendroglioma
Focus Adverse reactions; Therapeutic Use

Most Recent Events

24 Apr 2018 Status changed from active, no longer recruiting to completed.
06 Jun 2017 Results presented at the 53rd Annual Meeting of the American Society of Clinical Oncology
10 May 2017 According to a TRACON Pharmaceuticals media release, NCI will present detailed survival data and correlative analyses at the annual meeting of the American Society of Clinical Oncology (ASCO) in June 2017.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com